Dimitriadis K, Pyrpyris N, Beneki E
… +9 more, Meier D, Papanikolaou A, Dris E, Theofilis P, Antiochos P, Fournier S, Tzimas G, Aznaouridis K, Tsioufis K
Future Cardiol
· 2026 May · PMID 42036796
·
Full text
AIM: The pre-procedural presence of chronic total occlusions (CTO) in patients undergoing transcatheter aortic valve implantation (TAVI) could be a significant predictor of outcomes. This meta-analysis aims to investigat...AIM: The pre-procedural presence of chronic total occlusions (CTO) in patients undergoing transcatheter aortic valve implantation (TAVI) could be a significant predictor of outcomes. This meta-analysis aims to investigate whether CTO presence significantly alters outcomes in TAVI patients. METHODS: A systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. After study selection, a random effect meta-analysis was performed. RESULTS: Seven studies with a total of 15,162 patients undergoing TAVI were included. There was no significant difference regarding in-hospital [Relative Risk (RR): 1.13; 95% Confidence Interval (95% CI): 0.82-1.55] and 1-year all-cause mortality (RR: 1.58; 95% CI: 0.71-3.50). Patients with CTO exhibited significantly increased rates of myocardial infarction (RR: 1.27, 95% CI: 1.07-1.51) and reduced rates of new pacemaker implantation (RR: 0.88, 95% CI: 0.79-0.98). No differences were found in cardiogenic shock (RR: 1.18, 95% CI: 0.97-1.44), acute kidney injury (RR: 1.06, 95% CI: 0.88-1.28), vascular complications (RR: 1.10, 95% CI: 0.91-1.33), or bleeding (RR: 1.01, 95% CI: 0.89-1.14). CONCLUSION: In TAVI patients, pre-procedural unrevascularized CTO presence is not related to short- or mid-term increased mortality. Further studies are needed to identify predictors of adverse events and phenotypes benefiting from revascularization.
Picano E, Zagatina A, Cortigiani L
… +34 more, Padang R, Kane GC, Villarraga HR, Arruda-Olson AM, Lowenstein J, Arbucci R, Rodriguez-Zanella H, Safarova A, Timofeeva T, Bursi F, Boshchenko A, Zhuravleva O, Wang Y, Yin L, Peteiro Vazquez J, Manganelli F, Merli E, Soulis D, Saad A, Celutkiene J, Balkeviciene L, Kobal S, Djordjevic-Dikic A, Gaibazzi N, Borguesan-Daros C, Nikolic A, Ostojic M, Kovacevic-Preradovic T, Wierzbowska-Drabik K, Kasprzak JD, Gerra L, Carerj S, Ciampi Q, Pellikka PA
Future Cardiol
· 2026 May · PMID 42017616
·
Full text
Stress echocardiography (SE) has evolved beyond its traditional role of detecting coronary artery disease (CAD) through a single marker-regional wall motion abnormality (RWMA). This conventional approach, while guideline...Stress echocardiography (SE) has evolved beyond its traditional role of detecting coronary artery disease (CAD) through a single marker-regional wall motion abnormality (RWMA). This conventional approach, while guideline-embedded, faces a declining positivity rate and reduced prognostic power in today's diverse patient population. In response, SE has undergone a conceptual transformation into a multi-marker, comprehensive functional assessment of patient vulnerability. The modern multi-marker protocol, known as the ABCDE-SE, integrates five steps during a single stress test: Step A assesses RWMA for ischemia; Step B quantifies pulmonary congestion via B-lines and E/e'; Step C evaluates left ventricular volume response; Step D measures coronary flow velocity reserve for microvascular function; and Step E determines heart rate reserve for autonomic function. Each step identifies distinct pathophysiological mechanisms and actionable therapeutic targets, significantly refining risk stratification.Developed and validated over the past decade with the SE 2030 study (2016-2030), the flagship project of SIECVI, Italian Society of Echocardiography and Cardiovascular Imaging, and adopted by 50 laboratories from 20 countries, the ABCDE protocol represents a universal and widely accessible platform, applicable to all patients with suspected cardiac disease. It paves the way for personalized medicine by enabling tailored therapies targeted to the specific vulnerabilities.
Future Cardiol
· 2026 May · PMID 42015828
·
Full text
Dilated cardiomyopathy (DCM) is the most common pediatric cardiomyopathy and a leading cause of heart failure and cardiac transplantation in children. While a rare complication of maternal diabetes, the dilated phenotype...Dilated cardiomyopathy (DCM) is the most common pediatric cardiomyopathy and a leading cause of heart failure and cardiac transplantation in children. While a rare complication of maternal diabetes, the dilated phenotype of Infant of a Diabetic Mother (IDM) cardiomyopathy carries a high risk of morbidity and mortality. We report a term female neonate born to a mother with poorly controlled gestational diabetes (HbA1c 8.0%) who developed severe cardiogenic shock within 24 hours of life. Echocardiography confirmed DCM with profound biventricular dysfunction (initial left ventricular ejection fraction [LVEF] 28%, deteriorating to <17% within 5 days) and associated left ventricular non-compaction (LVNC) morphology. Despite maximal medical therapy, the infant's condition deteriorated, and she died on day 11 of life. Comprehensive diagnostic workup for alternative etiologies was limited by the rapid clinical course. This fatal case highlights the potential severity of the dilated form of IDM cardiomyopathy, which can be rapidly progressive and refractory to treatment. It underscores the critical importance of optimal glycemic control in pregnancy while acknowledging that alternative genetic or metabolic etiologies cannot be definitively excluded. This presentation should be recognized as a high-risk clinical entity distinct from the more common and often transient hypertrophic form.
Salibe-Filho W, Zorze Rossetto N, Tatagiba LS
… +5 more, de Deus MontAlverne Parente Y, Jardim CVP, Fernandes CJC, Alves-Junior JL, Souza R
Future Cardiol
· 2026 May · PMID 42009617
·
Full text
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling, right ventricular overload, and premature death. Despite advances achieved through endothelin receptor antago...Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling, right ventricular overload, and premature death. Despite advances achieved through endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogs, these agents primarily act as vasodilators and do not reverse underlying vascular pathology. Sotatercept, a first-in-class activin signaling modulator, restores the balance between pro- and antiproliferative signaling within the pulmonary vasculature via the TGF-β/activin-BMPR2 pathway, offering a novel disease-modifying mechanism. Following encouraging preclinical data, a series of clinical trials, PULSAR, SPECTRA, STELLAR, ZENITH, and HYPERION, demonstrated consistent efficacy across diverse PAH populations. Sotatercept significantly reduced pulmonary vascular resistance, improved exercise capacity, and decreased morbidity and mortality, including in patients receiving maximal background therapy. Across studies, adverse events were generally mild to moderate, with epistaxis, telangiectasia, and increased hemoglobin being the most common treatment-related events. Collectively, these findings establish sotatercept as a major advance in PAH therapy, marking a transition from purely vasodilatory approaches toward targeted modulation of vascular remodeling. By improving pulmonary hemodynamics and right ventricular function, sotatercept represents a new therapeutic option for improving clinical outcomes across different stages of PAH.
Almeida LGS, Carretta LTA, Falcão L
… +8 more, de Souza AM, Silva YP, de Oliveira MPP, Suruagy-Motta RFO, Dos Santos KDA, Dos Santos RTF, Surgik G, Andrade FA
Future Cardiol
· 2026 Apr · PMID 41992871
·
Full text
INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) has been explored as a therapy to enhance myocardial repair after acute myocardial infarction (AMI). Earlier meta-analyses of randomized controlled trials (RCTs...INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) has been explored as a therapy to enhance myocardial repair after acute myocardial infarction (AMI). Earlier meta-analyses of randomized controlled trials (RCTs) reported no significant improvement but recently published studies warranted an updated synthesis. METHODS: We searched PubMed, Embase, Cochrane Library, and Web of Science for RCTs comparing G-CSF with placebo or standard care in AMI. Primary outcomes were left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF). Secondary outcomes were mortality, reinfarction, restenosis, and revascularization. RESULTS: Eleven RCTs encompassing 1,073 participants were included. G-CSF significantly reduced LVEDV in echocardiography studies (MD: -4.39 mL; 95% CI -6.80, -1.98; < 0.001), whereas no effect was observed in MRI studies (MD: -0.19 mL; 95% CI -7.22, 6.84; = 0.958). LVEF improved in the echocardiography subgroup (MD: 6.76%; 95% CI 1.62, 11.90; = 0.010) but not in the MRI subgroup (MD: -0.08%; 95% CI -2.38, 2.22; = 0.947). LVESV showed no significant differences. No effects were seen for mortality, reinfarction, restenosis, or revascularization. CONCLUSION: G-CSF may confer structural benefits detectable by echocardiography, yet clinical outcomes remain unchanged. Larger, high-quality trials are needed to define its therapeutic role.
Mookadam M, Mookadam SA, Morris M
… +2 more, Pradhan S, Mookadam F
Future Cardiol
· 2026 May · PMID 41988791
·
Full text
INTRODUCTION: Uni-leaflet mitral valve (ULMV) is a rare congenital anomaly historically considered incompatible with long-term survival, yet increasing reports describe diagnosis in adulthood. We conducted a systematic r...INTRODUCTION: Uni-leaflet mitral valve (ULMV) is a rare congenital anomaly historically considered incompatible with long-term survival, yet increasing reports describe diagnosis in adulthood. We conducted a systematic review to characterize clinical presentation, anatomy, imaging findings, management, and outcomes in adults with ULMV. METHODS: Following PRISMA guidelines, major databases were searched from 1960 through January 2024. Eligible studies reported adult patients with confirmed ULMV. Data were extracted on demographics, valve morphology, symptoms, associated anomalies, imaging modalities, interventions, and outcomes. RESULTS: Thirty-six publications comprising 40 adult patients met inclusion criteria. Mean age at diagnosis was 50.5 years, with female predominance. Posterior leaflet hypoplasia or agenesis accounted for 97.5% of cases. Most patients were symptomatic, commonly with dyspnea or heart failure, and over half had moderate or greater mitral regurgitation. Atrial fibrillation, atrial septal defects, and aortic valve abnormalities were frequent comorbidities. Transthoracic echocardiography was used universally, with transesophageal and three-dimensional imaging providing incremental anatomical detail. Approximately one-third underwent mitral valve repair or replacement, with generally favorable outcomes. CONCLUSIONS: Adult ULMV demonstrates marked clinical and anatomical heterogeneity and may represent a developmental spectrum rather than a single entity. Standardized definitions and prospective registries are needed to improve risk stratification and guide management. PROTOCOL REGISTRATION: http://www.crd.york.ac.uk/prospero identifier is CRD420251083213.
Serafini L, Ricci A, Pezzola E
… +7 more, Legati M, Capasso F, Pugno Vanoni F, Geavlete O, Chioncel O, Metra M, Adamo M
Future Cardiol
· 2026 May · PMID 41978475
·
Full text
Tricuspid regurgitation (TR) has long been underestimated, traditionally viewed as a benign condition, yet contemporary evidence demonstrates its high prevalence and substantial adverse prognostic implications. Medical t...Tricuspid regurgitation (TR) has long been underestimated, traditionally viewed as a benign condition, yet contemporary evidence demonstrates its high prevalence and substantial adverse prognostic implications. Medical therapy remains limited, and although surgery has historically been the standard of care, many patients are referred at advanced stages, contributing to poor operative outcomes. Transcatheter tricuspid valve interventions (TTVI) have emerged as a valuable therapeutic option, showing consistent improvements in symptoms, quality of life (QoL), and heart failure hospitalizations (HFH), although a definitive survival benefit has not yet been established. Optimal management requires a comprehensive, multiparametric, and multidisciplinary approach. Key elements include careful assessment of TR etiology, clinical status, right heart failure stage, multimodality imaging, risk scores, and invasive hemodynamics. Integrating these factors enables appropriate patient selection, individualized treatment strategies, and avoidance of futile procedures. Ultimately, decisions regarding intervention and device choice should be guided by a dedicated multidisciplinary Heart Team within a specialized Heart Valve Center.
Chaaban N, Kastrup J, Rossing K
… +8 more, Schou M, Hove J, Buch P, Ekblond A, Johansen EM, Nørgaard MJ, Højgaard LD, Qayyum AA
Future Cardiol
· 2026 Apr · PMID 41879383
·
Full text
Heart failure (HF) remains a major clinical and healthcare challenge with high morbidity, mortality, and impaired quality of life (QOL). Approximately 30-40% of HF cases in the western world are of nonischemic heart fail...Heart failure (HF) remains a major clinical and healthcare challenge with high morbidity, mortality, and impaired quality of life (QOL). Approximately 30-40% of HF cases in the western world are of nonischemic heart failure (NIHF) origin; yet, regenerative therapies are lacking. Evidence suggests that systemic inflammation contributes to disease progression in NIHF, highlighting immunomodulation as a potential therapeutic target. Mesenchymal stromal cells (MSCs) possess regenerative and immunomodulatory properties, with adipose tissue derived stromal cells (ASCs) emerging as particularly promising. ARIISE is a Danish, multicenter, randomized, double-blinded, placebo-controlled study evaluating the efficacy and safety of intravenous allogeneic ASC therapy (C2C_ASC110) in patients with NIHF and reduced left ventricular ejection fraction (LVEF ≤ 45%). Ninety patients will be randomized to receive either C2C_ASC110 or placebo dimethyl sulfoxide (DMSO) (Cryostor®) intravenously twice 1 month apart, in addition to optimal guideline-directed medical therapy. The primary endpoint is a change in LVEF at 6-month follow-up after second ASC/placebo infusion. Secondary endpoints include other echocardiographic measurements, functional capacity, biomarkers, quality of life (QOL), and safety outcomes. If successful, ARIISE may establish clinical evidence for intravenous ASC therapy as a safe, feasible, and effective regenerative treatment for patients with NIHF. EU CT number: 2025-520837-22-00, UTN number: U1111-1315-7011, Clinicaltrials.gov number: NCT06840275.
Pál E, Párkányi V, Turschl TK
… +9 more, Fábián A, Ferencz A, Tokodi M, Tolvaj M, Nagy A, Kovács A, Merkely B, Lakatos BK, Ladányi Z
Future Cardiol
· 2026 Apr · PMID 41877665
·
Full text
Right ventricular (RV) function is a major determinant of clinical outcomes in patients undergoing cardiac surgery and transcatheter interventions. Although left ventricular morphology and function have been the traditio...Right ventricular (RV) function is a major determinant of clinical outcomes in patients undergoing cardiac surgery and transcatheter interventions. Although left ventricular morphology and function have been the traditional focus of preprocedural assessment, RV dysfunction is now recognized as an important predictor of morbidity and mortality. Therefore, inclusion of RV-related parameters in preprocedural risk assessment is on the rise. This review summarizes current evidence on the role of RV function in various cardiac diseases that require surgery or interventions. Conventional two-dimensional echocardiographic parameters, such as tricuspid annular plane systolic excursion, RV fractional area change, and peak systolic tissue Doppler velocity, provide limited information due to the complex RV geometry. Advanced imaging techniques, including speckle-tracking, three-dimensional echocardiography, and cardiac magnetic resonance imaging, enable more accurate quantification of RV volumes, ejection fraction, strain, RV motion components and RV-pulmonary artery coupling, and have demonstrated superior prognostic value. Therefore, a comprehensive assessment of RV function using advanced imaging techniques should be incorporated into routine clinical practice to improve risk stratification and preprocedural planning before cardiac surgery and transcatheter interventions. However, it is necessary to standardize imaging protocols and define validated reference thresholds to support the clinical implementation of these state-of-the-art parameters.
Future Cardiol
· 2026 Mar · PMID 41851971
·
Full text
The role of intra-aortic balloon pump (IABP) use in optimizing patients for durable left ventricular assist device (LVAD) implantation is being reevaluated in the era of modern centrifugal, magnetically levitated pumps....The role of intra-aortic balloon pump (IABP) use in optimizing patients for durable left ventricular assist device (LVAD) implantation is being reevaluated in the era of modern centrifugal, magnetically levitated pumps. A comprehensive PubMed literature review was conducted including studies published from the 1980s through 2025, corresponding to the era in which IABP therapy became established as standard of care. Emerging data suggest that IABP may provide meaningful physiologic unloading, improve right-sided pressures, and enhance end-organ perfusion in select LVAD candidates. Axillary-access IABP has further expanded its utility by enabling early ambulation and prolonged support consistent with contemporary enhanced recovery principles. Comparative analyses indicate that while complications such as limb ischemia and bleeding remain relevant, preoperative IABP does not appear to worsen postoperative outcomes and may offer hemodynamic advantages without increasing short-term mortality. Nevertheless, evidence remains heterogeneous, and direct comparisons with percutaneous ventricular assist devices and extracorporeal membrane oxygenation (ECMO) are limited. This review synthesizes current data regarding IABP physiology, access strategy, patient selection, perioperative outcomes, and areas of ongoing uncertainty in relation to LVAD implantation. Improved mechanistic understanding and prospective standardized investigations will be essential to define the appropriate role of IABP within modern LVAD optimization pathways.
Shokravi A, Sharma S, Singh R
… +2 more, Seth J, Mancini GBJ
Future Cardiol
· 2026 Apr · PMID 41851014
·
Full text
BACKGROUND: Patients with dialysis-dependent chronic kidney disease (CKD) have a high cardiovascular burden, prompting interest in fish oils or long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) as potential risk...BACKGROUND: Patients with dialysis-dependent chronic kidney disease (CKD) have a high cardiovascular burden, prompting interest in fish oils or long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) as potential risk-reducing therapies in this population. METHODS: We conducted a systematic review and meta-analysis of studies in adults receiving dialysis that assessed associations between n-3 PUFA supplementation, baseline levels, or dietary intake and CV outcomes, or all-cause mortality. Hazard ratios (HRs) were pooled using random-effects models. RESULTS: Twelve studies met inclusion criteria. In hemodialysis-dependent CKD, fish oil supplementation lowered cardiovascular events by 44% (HR 0.56; 95% CI 0.46-0.68) and myocardial infarction by 48% (HR 0.52; 95% CI 0.34-0.78). Higher baseline n-3 PUFA levels were associated with a 31% reduction in all-cause mortality (HR 0.69; 95% CI 0.54-0.88). Higher dietary n-3 PUFA intake showed a non-significant trend toward lower all-cause mortality (HR 0.92; 95% CI 0.79-1.08). CONCLUSION: In dialysis-dependent CKD, higher n-3 PUFA exposure through fish oil supplementation or higher baseline levels was associated with fewer cardiovascular events and all-cause mortality. Appropriately dosed n-3 PUFA supplementation represents a promising cardiovascular risk reduction strategy in dialysis-dependent CKD, although confirmatory randomized trials are warranted.
Future Cardiol
· 2026 Apr · PMID 41841199
·
Full text
Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, requiring precise risk prediction models for effective prevention and management. This review maps and evaluates globally utilized...Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, requiring precise risk prediction models for effective prevention and management. This review maps and evaluates globally utilized and country-specific CVD risk prediction models, including the Framingham Risk Score, Pooled Cohort Equations, PREVENT, WHO/ISH Risk Charts, INTERHEART, and SCORE2. A structured literature search was conducted using PubMed and Google Scholar, from which 30 relevant studies were selected. Most of the models integrate traditional risk factors such as age, sex, blood pressure, cholesterol, and smoking status to estimate CVD risk. While these models demonstrate moderate to good discrimination (C-statistics ranging from 0.66 to 0.80) and validation, their applicability varies across populations, with concerns about overestimation or underestimation in non-original cohorts. Notably, the WHO/ISH and Globorisk models address global diversity by incorporating regional calibrations, making them suitable for low- and middle-income countries. Similarly, the country-specific risk scores outperform global models due to their incorporation of local socio-demographics. Limitations persist across existing models, including the underrepresentation of younger individuals, ethnic minorities, and the exclusion of emerging risk factors. Future efforts must prioritize the development of locally validated, population-specific models to support equitable and effective CVD risk assessment and prevention.
Future Cardiol
· 2026 Mar · PMID 41805132
·
Full text
Right-ventricular outflow tract dysfunction is a common late sequela of congenital heart disease, particularly after tetralogy of Fallot repair. Balloon-expandable valves such as Melody and Sapien have transformed care f...Right-ventricular outflow tract dysfunction is a common late sequela of congenital heart disease, particularly after tetralogy of Fallot repair. Balloon-expandable valves such as Melody and Sapien have transformed care for conduits and bioprostheses, but until recently most patients with large or irregular outflow tracts were not candidates for percutaneous therapy. This review appraises the Venus P-Valve, the first self-expanding transcatheter pulmonary valve for large right-ventricular outflow tracts, summarizing evidence on efficacy, safety, and regulatory status. We performed a narrative review of feasibility studies, multicenter registries, national databases, and comparative analyses reporting outcomes with this device. More than 600 implantations have been reported worldwide. Procedural success consistently exceeds 95%, with immediate restoration of pulmonary valve competence, low residual gradients, and right-ventricular reverse remodeling within 6-12 months. Follow-up to five years demonstrates durable performance and a low need for reintervention. Comparative studies suggest hemodynamic outcomes similar to surgical pulmonary valve replacement, with shorter hospitalization and lower morbidity in appropriately selected patients; pediatric series confirm feasibility with sustained benefit. Reported adverse events have been infrequent. The Venus P-Valve expands transcatheter options for large native or patched outflow tracts and currently holds CE marking in Europe and NMPA approval in China.
Sembo TWS, Fatehi Hassanabad A, Schultz RD
… +2 more, Webb NA, Kent WDT
Future Cardiol
· 2026 Mar · PMID 41784257
·
Full text
Lupus is a systemic disease characterized by the formation of immune complexes and antibodies. Common manifestations of lupus include rashes, ulcers, and neurologic disease. Lupus has cardiac involvement in greater than...Lupus is a systemic disease characterized by the formation of immune complexes and antibodies. Common manifestations of lupus include rashes, ulcers, and neurologic disease. Lupus has cardiac involvement in greater than 50% of cases. It can present as pericarditis, myocarditis, and valvular disease. Although lupus has known associated cardiac manifestations, it is not classically associated with quadricuspid aortic valve. Herein, we present a rare case of quadricuspid aortic valve in a patient with lupus and triple valve disease requiring surgical intervention.
Alkasabrah O, Agrawal SP, Hafeez A
… +7 more, Farid Gadelmawla A, Mohammed YA, Takawy M, Ibrahim S, Joshi DK, Jain H, Aronow WS
Future Cardiol
· 2026 Apr · PMID 41772835
·
Full text
BACKGROUND: Inflammatory bowel disease (IBD) is associated with systemic inflammation and increased cardiovascular risk, but its impact on in-hospital outcomes after acute myocardial infarction (MI) remains unclear. METH...BACKGROUND: Inflammatory bowel disease (IBD) is associated with systemic inflammation and increased cardiovascular risk, but its impact on in-hospital outcomes after acute myocardial infarction (MI) remains unclear. METHODS: We conducted a retrospective cohort study using the National Inpatient Sample (2016-2022) to identify hospitalizations for acute MI and compared outcomes between patients with and without IBD. Multivariate logistic regression was used to evaluate the association between IBD and post-MI complications. Associations were summarized as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). RESULTS: Among 1,456,940 MI hospitalizations, 7,430 had IBD. After adjustment, IBD was associated with higher odds of mortality (aOR 3.32, 95% CI 3.18-3.47; < 0.0001), left ventricular rupture (aOR 4.46, 95% CI 3.16-6.28; < 0.0001), left ventricular aneurysm (aOR 1.93, 95% CI 1.61-2.31; < 0.0001), acute mitral regurgitation (aOR 9.80, 95% CI 6.81-14.10; < 0.0001), and stent restenosis (aOR 1.16, 95% CI 1.07-1.26; = 0.0002). IBD was also associated with longer hospital stay (coefficient 2.13 days, 95% CI 2.03-2.23; < 0.0001) and higher total hospital charges.Conclusion: IBD was associated with worse in-hospital outcomes and higher resource utilization after MI in this nationwide hospitalization-level analysis.
Yu J, Zhu N, Zhu L
… +3 more, Pan X, Zhu Z, TRAMPERS investigators
Future Cardiol
· 2026 Mar · PMID 41739727
·
Full text
Severe pure native aortic regurgitation (PNAR), if untreated, carries a high mortality rate. Many patients are ineligible for surgical aortic valve replacement (SAVR) due to high risk. While transcatheter aortic valve re...Severe pure native aortic regurgitation (PNAR), if untreated, carries a high mortality rate. Many patients are ineligible for surgical aortic valve replacement (SAVR) due to high risk. While transcatheter aortic valve replacement (TAVR) is an alternative, its application in PNAR is challenged by anatomical factors like the absence of calcification for anchoring. Dedicated transcatheter devices are not widely available, leading to the off-label use of self-expanding valves, though robust comparative evidence is lacking. The TRAMPERS trial is a prospective, multicenter, controlled, open-label clinical trial that aims to evaluate the safety and effectiveness of transfemoral TAVR using the VitaFlow™ Liberty self-expanding valve system compared to the J-Valve system in patients with severe PNAR. A total of 180 patients with severe PNAR will be enrolled across four centers in China and evaluated by a heart team. Patients will be allocated in a 1:1 ratio to the VitaFlow™ group (n = 90) or the J-Valve control group (n = 90). The primary endpoint is a composite of all-cause mortality, disabling stroke and rehospitalization for heart failure at 12 months post-procedure, assessed for non-inferiority. Secondary endpoints include procedural complications, clinical events, health status and cost-effectiveness. All endpoints are adjudicated according to VARC-3 criteria.Clinical Trial Registration:NCT06818084 (ClinicalTrials.gov).
Cappadona I, Pagano M, Cardile D
… +8 more, Patti E, Ansaldo A, Anselmo A, De Luca R, Piccione M, Sottile F, Calabrò RS, Corallo F
Future Cardiol
· 2026 Mar · PMID 41728841
·
Full text
INTRODUCTION: Takotsubo Syndrome (TTS) presents as an acute heart disease characterized by left ventricular dysfunction. The exact cause is not yet known; however, it is thought that it may be caused by acute emotional o...INTRODUCTION: Takotsubo Syndrome (TTS) presents as an acute heart disease characterized by left ventricular dysfunction. The exact cause is not yet known; however, it is thought that it may be caused by acute emotional or physical events and the subsequent release of catecholamines. This review investigated the presence of psychological and neurological disorders associated with TTS. METHODS: Studies evaluating the presence of psychological and neurological disorders in TTS were reviewed. Search was performed on the Cochrane, PubMed, Embase, Scopus, and Web of Science Databases. Of the initial 763 studies, 12 met the inclusion criteria. RESULTS: All studies analyzed demonstrated the presence of psychological disorders, and six also demonstrated the presence of neurological disorders. In particular, associations emerged with psychological disorders such as depression and anxiety. Major neurological disorders identified included migraine, epilepsy, and cerebral hemorrhage. In addition, structural and volumetric brain changes were observed in people with TTS through neuroimaging studies. CONCLUSIONS: Further studies evaluating the still poorly understood etiology of the syndrome are needed so that an appropriate early diagnosis can be made. Further studies should investigate the effectiveness of psychotherapeutic treatments in order to improve symptom management, prognosis, and more adequately manage any relapse.
Javaid SS, Maqbool U, Shaikh MA
… +14 more, Ijaz O, Musani S, Yousafzai ZA, Siddique A, Malik NQ, Shafique R, Rukh S, Jawed F, Ahmed F, Bashir H, Kanpurwala MA, Aziz AA, Dang AK, Shabbir MS
Future Cardiol
· 2026 Mar · PMID 41720751
·
Full text
BACKGROUND: MASLD is a prevalent liver condition linked to increased cardiovascular risks and higher mortality, particularly among those with AMI. This study explores the impact of MASLD on clinical outcomes in patients...BACKGROUND: MASLD is a prevalent liver condition linked to increased cardiovascular risks and higher mortality, particularly among those with AMI. This study explores the impact of MASLD on clinical outcomes in patients with AMI, focusing on mortality, hospital charges, and length of stay. METHODS: The NIS database from 2018 to 2020 was utilized to evaluate the prevalence, mortality, costs, and resource use related to primary AMI hospitalizations with and without MASLD. RESULTS: A total of 1,885,105 hospitalizations with AMI were identified, with 39,000 (2.1%) patients having AMI and MASLD. The mean length of hospital stay was significantly longer in AMI patients with MASLD (5.58 days) compared to those without MASLD (4.34 days) ( < 0.001). In-hospital mortality was significantly higher in patients with MASLD (7.8%) compared to those without (4.6%), with 45% increased odds of mortality (OR: 1.45, < 0.001). The hospital charges were also higher for patients with MASLD ($128,494) compared to non-MASLD patients ($104,836) ( < 0.001), with regression analysis indicating an additional $9,911 in charges ( < 0.001). CONCLUSIONS: AMI patients with MASLD experience higher mortality rates, longer hospital stays, and increased healthcare costs. Further research is essential to develop improved management strategies.